Prof Sven Mahner talks to ecancer at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about a retrospective study looking at treatment of vulva cancer in the adjuvant setting.

Vulva cancer, a rare disease with an increase of incidence especially in younger patients, has very few trials in progress due to the rarity of the disease.

This study on adjuvant treatment collected data and analysed treatment modalities and prognostic factors retrospectively.

Results looked at 500 node positive patients and that found those treated with adjuvant therapy had 30 percent longer survival than those without.

Filming supported by Amgen